Crinetics Pharmaceuticals Stock Forecast, Price & News

Crinetics Pharmaceuticals (NASDAQ:CRNX) Frequently Asked Questions

Is Crinetics Pharmaceuticals a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Crinetics Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Crinetics Pharmaceuticals stock.
View analyst ratings for Crinetics Pharmaceuticals or view top-rated stocks.

How has Crinetics Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Crinetics Pharmaceuticals' stock was trading at $15.50 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CRNX shares have increased by 17.4% and is now trading at $18.20.
View which stocks have been most impacted by COVID-19.

When is Crinetics Pharmaceuticals' next earnings date?

Crinetics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, March 29th 2022.
View our earnings forecast for Crinetics Pharmaceuticals.

How were Crinetics Pharmaceuticals' earnings last quarter?

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) announced its earnings results on Friday, November, 5th. The company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.72) by $0.01.
View Crinetics Pharmaceuticals' earnings history.

What price target have analysts set for CRNX?

6 equities research analysts have issued 1-year price targets for Crinetics Pharmaceuticals' shares. Their forecasts range from $28.00 to $45.00. On average, they expect Crinetics Pharmaceuticals' share price to reach $36.80 in the next year. This suggests a possible upside of 102.2% from the stock's current price.
View analysts' price targets for Crinetics Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Crinetics Pharmaceuticals' key executives?

Crinetics Pharmaceuticals' management team includes the following people:

• Scott R. Struthers, President, Chief Executive Officer & Director
• Jeff E Knight, Chief Operating Officer
• Marc J. S. Wilson, Chief Financial Officer
• Robert Flath, Finance Director
• Stephen F. Betz, Chief Scientific Officer (LinkedIn Profile)

What is R. Scott Struthers, Ph.D.'s approval rating as Crinetics Pharmaceuticals' CEO?

2 employees have rated Crinetics Pharmaceuticals CEO R. Scott Struthers, Ph.D. on Glassdoor.com. R. Scott Struthers, Ph.D. has an approval rating of 100% among Crinetics Pharmaceuticals' employees. This puts R. Scott Struthers, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Crinetics Pharmaceuticals' key competitors?

Some companies that are related to Crinetics Pharmaceuticals include Galapagos (GLPG), Hypera (HYPMY), CureVac (CVAC), Apellis Pharmaceuticals (APLS), Karuna Therapeutics (KRTX), Dicerna Pharmaceuticals (DRNA), Prestige Consumer Healthcare (PBH), Pacira BioSciences (PCRX), PTC Therapeutics (PTCT), Amicus Therapeutics (FOLD), Cytokinetics (CYTK), Insmed (INSM), Zentalis Pharmaceuticals (ZNTL), Emergent BioSolutions (EBS) and Sage Therapeutics (SAGE).
View all of CRNX's competitors.

What other stocks do shareholders of Crinetics Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Crinetics Pharmaceuticals investors own include SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), G1 Therapeutics (GTHX), Kura Oncology (KURA), Otonomy (OTIC), Selecta Biosciences (SELB), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS) and Applied Genetic Technologies (AGTC).

When did Crinetics Pharmaceuticals IPO?

(CRNX) raised $80 million in an initial public offering (IPO) on Wednesday, July 18th 2018. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Leerink Partners and Piper Jaffray acted as the underwriters for the IPO.

What is Crinetics Pharmaceuticals' stock symbol?

Crinetics Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRNX."

How do I buy shares of Crinetics Pharmaceuticals?

Shares of CRNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Crinetics Pharmaceuticals' stock price today?

One share of CRNX stock can currently be purchased for approximately $18.20.

How much money does Crinetics Pharmaceuticals make?

Crinetics Pharmaceuticals has a market capitalization of $864.50 million and generates $70 thousand in revenue each year. The company earns $-73.81 million in net income (profit) each year or ($2.78) on an earnings per share basis.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals employs 93 workers across the globe.

What is Crinetics Pharmaceuticals' official website?

The official website for Crinetics Pharmaceuticals is www.crinetics.com.

Where are Crinetics Pharmaceuticals' headquarters?

Crinetics Pharmaceuticals is headquartered at 10222 Barnes Canyon Road Building #2, San Diego CA, 92121.

How can I contact Crinetics Pharmaceuticals?

Crinetics Pharmaceuticals' mailing address is 10222 Barnes Canyon Road Building #2, San Diego CA, 92121. The company can be reached via phone at (858) 450-6464 or via email at [email protected].